09.11.2016 • NewsAdamaChemChinacommission

EU to Probe Syngenta-ChemChina Deal in Depth

(c) AVTG
(c) AVTG

The European Commission has launched an in-depth investigation into ChemChina’s plan to acquire Swiss agrochemicals producer Syngenta for $43 billion. The EU regulatory agency said the probe will explore whether the combination of Syngenta’s pesticides with the generic alternatives produced by Adama Agricultural Solutions, an Israeli company controlled by ChemChina, presents competition concerns.

EU officials said they expect to complete their review by Mar. 15, 2017, about the same time the competition authority plans to make a decision on the planned merger of Dow and DuPont, which also partly impacts the agriculture sector. Simultaneously it will be looking at the proposed takeover of US seeds giant Monsanto by Germany’s Bayer. Regulatory  authorities in the US, Canada, Brazil and Australia are also reviewing the deals.

According to the Commission, Syngenta and Adama have “strong overlapping portfolios” in crop protection products such as herbicides, insecticides, fungicides and plant growth regulators, markets that are already highly concentrated. “This deal would lead to the combination of a leading crop protection company with one of its main generic competitors.

Therefore we need to carefully assess whether the proposed merger would lead to higher prices or a reduced choice for farmers," said EU Competition Commissioner Margrethe Vestager, Presenting company results in late October, Syngenta CEO Erik Fyrwald said regulatory approval of the Swiss company’s deal with ChemChina was likely to be delayed into the first quarter of 2017 as regulators seek more information. Due to what it said was a lack of information, the Commission in mid-October again halted its review of the Dow-DuPont merger plans.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.